[Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Abstract

PURPOSE:

To evaluate the resolution rate in patients with symptomatic vitreomacular traction (≤ 1500 μm) with or without macular holes (≤ 400 μm) after therapy with intravitreal ocriplasmin (Jetrea®) injection in a clinical setting.

METHODS:

Until now we have prospectively examined 21 eyes of 21 consecutive patients with symptomatic vitreomacular traction with or without macular holes who underwent intravitreal operative injection of 0.1 ml ocriplasmin. The best corrected visual acuity and high-resolution optical coherence tomography (SD-OCT) ultrastructural parameters were measured before injection and again 1, 3 and 4 months after treatment. The numbers of resolved vitreomacular traction and closed macular holes were documented.

RESULTS:

Vitreomacular traction was resolved in 15 out of 21 (71 %) eyes. Of the five eyes which initially presented with vitreomacular traction with macular holes, all showed resolution of vitreomacular traction but only two of the macular holes were closed. The average best corrected visual acuity was 0.38 logMAR (± 0.23) at baseline and 0.43 logMAR (± 0.28), 0.38 logMAR (± 0.27) and 0.36 logMAR (± 0.24) 1, 3 and 4 months after injection, respectively. The average foveal thickness was 355.95 μm (± 114.53 μm) at baseline, reducing to 304.61 μm (± 100.91 μm), 308.00 μm (±76.17 μm) and 277.50 μm (± 26.24 μm) after 1, 3 and 4 months, respectively.

CONCLUSION:

In this ongoing study there was a high percentage of resolution of vitreomacular traction (71 %) 1 month after intravitreal operative injection of Jetrea® and closure of two out of five macular holes. This was further associated with stabilization of visual acuity and reduction of foveal thickness. Further investigations are necessary to document the effectiveness of the pharmacological vitreolysis in a clinical setting.

• Authors: M Maier, S Abraham, C Frank, N Feucht, C P Lohmann
• Journal: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft (Ophthalmologe) Vol. 112 Issue 12 Pg. 990-4 (Dec 2015) ISSN: 1433-0423 [Electronic] Germany
• Vernacular Title: Ocriplasmin zur Behandlung der symptomatischen vitreomakulären Traktion mit und ohne Makulaforamen. Erste klinische Erfahrungen.
• PMID: 26062717 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antifibrinolytic Agents
• Peptide Fragments
• microplasmin
• Fibrinolysin

Topics

• Aged
• Antifibrinolytic Agents (administration & dosage)
• Female
• Fibrinolysin (administration & dosage)
• Humans
• Intravitreal Injections
• Male
• Peptide Fragments (administration & dosage)
• Pilot Projects
• Retinal Perforations (diagnosis, drug therapy, pathology)
• Tissue Adhesions (diagnosis, drug therapy, pathology)
• Treatment Outcome
• Vision Disorders (diagnosis, etiology, prevention & control)
• Visual Acuity
• Vitreous Detachment (diagnosis, drug therapy, pathology)